Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
05 oct. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
21 mai 2015 16h05 HE
|
Otonomy, Inc.
Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067
Achieved statistical significance on...
Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update
12 mai 2015 16h01 HE
|
Otonomy, Inc.
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
07 mai 2015 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present at Two Upcoming Investor Conferences
06 mai 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Appoints George Morrow to Board of Directors
30 avr. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference
21 avr. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients
20 avr. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...